
---
title: '辉瑞新冠口服药允许5家中国药企免费生产？企业回应称在核实'
categories: 
 - 金融
 - 证券时报网
 - 快讯
headimg: 'https://picsum.photos/400/300?random=2132'
author: 证券时报网
comments: false
date: Thu, 17 Mar 2022 14:15:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=2132'
---

<div>   
<p>证券时报e公司讯，3月17日，有消息称，日内瓦药品专利池（Medicines PatentPool, MPP）组织宣布，已与35家药企签署协议，允许其生产辉瑞新冠口服药Paxlovid成分之一奈玛特韦（nirmatrelvir）原料药或制剂，包括上海迪赛诺、<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SS600521" style="color: #2f67d1;text-decoration: none;" code="600521" target="_blank">华海药业</a>、<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ000739" style="color: #2f67d1;text-decoration: none;" code="000739" target="_blank">普洛药业</a>、<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SS600196" style="color: #2f67d1;text-decoration: none;" code="600196" target="_blank">复星医药</a>、<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SS603456" style="color: #2f67d1;text-decoration: none;" code="603456" target="_blank">九洲药业</a>等5家中国企业。对此，<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SS600521" style="color: #2f67d1;text-decoration: none;" code="600521" target="_blank">华海药业</a>方面表示，还在核实中，还不了解具体情况。<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SS600196" style="color: #2f67d1;text-decoration: none;" code="600196" target="_blank">复星医药</a>表示，官方消息还没出来。(澎湃新闻)</p>

                  
</div>
            